PPI Modulators of E6 as Potential Targeted Therapeutics for Cervical Cancer: Progress and Challenges in Targeting E6

Area of Science:

• Oncology
• Virology
• Drug Discovery

Background:

• Advanced cervical cancer treatment relies on cytotoxic therapies with limited efficacy and significant toxicity.
• Current therapeutic options lack effectiveness, necessitating the development of novel treatment strategies.
• Targeted therapies against oncogenic host cellular targets have yielded minimal survival benefits over four decades.

Purpose of the Study:

• To review current knowledge on E6 oncoprotein as a therapeutic target in cervical cancer.
• To summarize progress and challenges in developing E6 protein-protein interaction (PPI) inhibitors.
• To explore potential approaches for identifying novel and potent E6 PPI inhibitors.

Main Methods:

• Literature review of research on E6 oncoprotein and its role in cervical cancer.
• Analysis of studies reporting peptide and small-molecule modulators of E6 PPIs.
• Evaluation of the characterization of these modulators in preclinical and clinical settings.

Main Results:

• The E6 oncoprotein inactivates cellular antitumor proteins via PPIs, presenting a viable therapeutic target.
• Several peptide and small-molecule E6 PPI modulators have been identified in cell-based models.
• Limited characterization of these compounds in animal or human subjects hinders clinical translation.

Conclusions:

• Targeting E6 PPIs is a promising strategy for novel cervical cancer therapeutics.
• Significant research is required to optimize identified E6 inhibitors.
• Further development is crucial to accelerate the discovery of potent and effective E6-targeted therapies.